Pargyline pretreatment prevents immunological changes induced by MPTP in mice.
The relationship between the central dopaminergic and the immune system is poorly understood. Experimental work suggest that damage of the nigrostriatal system may influence immunity. Immunological abnormalities have been described in Parkinson's disease and in a mouse model of this disorder induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). In this report, we present evidence that reduced numbers of L3T4 T cells in blood, and diminished primary antibody response to sheep erythrocytes in MPTP treated mice can be restored by pargyline pretreatment. Since pargyline prevents dopamine depletion in the striatum in MPTP treated animals, our data extend previous experimental observations and support a possible role for dopamine in immune regulation.
Bieganowska
K
K
Institute of Psychiatry and Neurology, Warsaw, Poland.
Czonkowska
A
A
Korlak
J
J
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine / Q000037:antagonists & inhibitors* / Q000494:pharmacology*; D000818:Animals; D000917:Antibody Formation / Q000187:drug effects; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects; D003342:Corpus Striatum / Q000187:drug effects; D018492:Dopamine Antagonists / Q000494:pharmacology; D004334:Drug Administration Schedule; D007109:Immunity / Q000187:drug effects*; D016131:Lymphocyte Subsets / Q000187:drug effects; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D010293:Pargyline / Q000008:administration & dosage* / Q000633:toxicity*; D010587:Phagocytosis / Q000187:drug effects; D013378:Substantia Nigra / Q000187:drug effects; D014409:Tumor Necrosis Factor-alpha / Q000187:drug effects
D018492:Dopamine Antagonists; D014409:Tumor Necrosis Factor-alpha; D010293:Pargyline; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine